Advertisement

Stem Cell Reviews and Reports

, Volume 12, Issue 1, pp 90–104 | Cite as

One Standardized Differentiation Procedure Robustly Generates Homogenous Hepatocyte Cultures Displaying Metabolic Diversity from a Large Panel of Human Pluripotent Stem Cells

  • Annika Asplund
  • Arvind Pradip
  • Mariska van Giezen
  • Anders Aspegren
  • Helena Choukair
  • Marie Rehnström
  • Susanna Jacobsson
  • Nidal Ghosheh
  • Dorra El Hajjam
  • Sandra Holmgren
  • Susanna Larsson
  • Jörg Benecke
  • Mariela Butron
  • Annelie Wigander
  • Karin Noaksson
  • Peter Sartipy
  • Petter Björquist
  • Josefina Edsbagge
  • Barbara Küppers-Munther
Article

Abstract

Human hepatocytes display substantial functional inter-individual variation regarding drug metabolizing functions. In order to investigate if this diversity is mirrored in hepatocytes derived from different human pluripotent stem cell (hPSC) lines, we evaluated 25 hPSC lines originating from 24 different donors for hepatic differentiation and functionality. Homogenous hepatocyte cultures could be derived from all hPSC lines using one standardized differentiation procedure. To the best of our knowledge this is the first report of a standardized hepatic differentiation procedure that is generally applicable across a large panel of hPSC lines without any adaptations to individual lines. Importantly, with regard to functional aspects, such as Cytochrome P450 activities, we observed that hepatocytes derived from different hPSC lines displayed inter-individual variation characteristic for primary hepatocytes obtained from different donors, while these activities were highly reproducible between repeated experiments using the same line. Taken together, these data demonstrate the emerging possibility to compile panels of hPSC-derived hepatocytes of particular phenotypes/genotypes relevant for drug metabolism and toxicity studies. Moreover, these findings are of significance for applications within the regenerative medicine field, since our stringent differentiation procedure allows the derivation of homogenous hepatocyte cultures from multiple donors which is a prerequisite for the realization of future personalized stem cell based therapies.

Keywords

Hepatocyte differentiation Human induced pluripotent stem cells Human embyronic stem cells Liver Toxicity Cellular therapy 

Notes

Acknowledgments

We thank other members of Takara Bio Europe AB and Skövde University who have provided assistance and technical help through-out this project.

Supported by the IMI-JU project MIP-DILI (grant 115336), the Seventh Framework Program project InnovaLiv (grant 278152), and the Knowledge Foundation (grants 2010/0069, 2012/0310, 2013/89).

Disclosure of Potential Conflicts of Interest

All authors are or have been employed by Takara Bio Europe AB (former Cellartis AB) when this study was performed.

Author Contributions

Annika Asplund: Collection, assembly, analysis, and interpretation of data, manuscript writing.

Anders Aspegren: Conception and design, data analysis and interpretation.

Arvind Pradip, Mariska van Giezen, Marie Rehnström, Susanna Jacobsson, Nidal Ghosheh, Dorra El Hajjam, Sandra Holmgren, Susanna Larsson, Jörg Benecke, Mariela Butron, Annelie Wigander: Collection, assembly and analysis of data.

Helena Choukair, Karin Noaksson: Analysis and interpretation of data.

Peter Sartipy, Josefina Edsbagge: Interpretation of data, manuscript writing.

Petter Björquist: Conception and design, manuscript writing.

Barbara Küppers-Munther: Conception and design, assembly, analysis, and interpretation of data, manuscript writing.

All: Final approval of manuscript

Supplementary material

12015_2015_9621_Fig7_ESM.gif (416 kb)
Suppl. Figure 1

Homogenous expression of the hepatic marker HNF4α in hepatocyte cultures derived from 16 hPSC lines. Immunocytochemical staining of hepatocyte cultures derived from 12 hiPSC and 4 hESC lines after 28 days of differentiation for the hepatic marker HNF4α. Nuclear counterstaining with DAPI. On average 93.8 % ± 0.7 (SEM) of DAPI-stained nuclei are immuno-positive for HNF4α. Percentages for the individual hPSC lines are given in the respective HNF4α-picture. The scale bars represent 100 μM. Abbreviations: DAPI = 4′,6-diamidino-2-phenylindol; HNF4α = hepatocyte nuclear factor 4α. (GIF 415 kb)

12015_2015_9621_MOESM1_ESM.tif (10.8 mb)
High Resolution Image (TIFF 11048 kb)
12015_2015_9621_Fig8_ESM.gif (107 kb)
Suppl. Figure 2

Expression of hepatic markers in hPSC-derived hepatocytes after 28 days of differentiation. Immunocytochemical stainings of hepatocyte cultures derived from the hiPSC lines ChiPSC4 and P11012, and the hESC lines SA121 and SA461 for the hepatic markers Cytokeratin 18 (CK18), α1-Antitrypsin (a1-AT), and Albumin (Alb). Scale bars represent 100 μM. Abbreviations: α1-AT = α1-Antitrypsin; Alb = Albumin; CK18 = Cytokeratin 18. (GIF 106 kb)

12015_2015_9621_MOESM2_ESM.tif (2.7 mb)
High Resolution Image (TIFF 2782 kb)
12015_2015_9621_Fig9_ESM.gif (98 kb)
Suppl. Figure 3

Inter-individual variation of mRNA expression of hepatic genes in freshly isolated primary human hepatocytes. QPCR analysis of mRNA expression of the hepatic markers α1-Antitrypsin and Albumin (A,B), the drug-metabolizing enzymes CYP1A1, 1A2, 2C9, 3A4, 3A5, and 3A7 (C-H), the phase II enzymes GSTA1-1 and UGT2B7 (I,J), and the transporters NTCP and OATP1B1 (K,L) in freshly isolated human primary hepatocytes from 7 different donors. Expression levels are normalized to CEBPα serving as a house-keeping gene and a calibrator mix (set as 1) and presented as relative quantification. Abbreviations: α1-AT = α1-Antitrypsin; CEBPα = CCAAT/enhancer binding protein α; CYP = Cytochrome P450 enzyme; GSTA1-1 = glutathione-S-transferase A1-1; hphep = human primary hepatocytes; NTCP = Sodium taurocholate co-transporting polypeptide; OATP1B1 = organic anion transporter family, member 1B1; UGT2B7 = UDP-glucuronosyltransferase 2B7. (GIF 97 kb)

12015_2015_9621_MOESM3_ESM.tif (1.7 mb)
High Resolution Image (TIFF 1722 kb)
12015_2015_9621_Fig10_ESM.gif (1.4 mb)
Suppl. Figure 4

Homogenous hepatocyte cultures repeatedly derived from 9 hPSC lines. A Representative phase contrast pictures of homogenous hepatocyte populations obtained in repeated experiments from the hiPSC lines ChiPSC4, ChiPSC17, ChiPSC22, ChiPSC18, P11012, P11032, and the hESC lines SA121, SA461, Val9 on between day 21 and 28 after start of differentiation. Per repeated differentiation experiment one picture is shown. The scale bar represents 100 μm. (GIF 1444 kb)

12015_2015_9621_MOESM4_ESM.tif (69.9 mb)
High Resolution Image (TIFF 71546 kb)

References

  1. 1.
    Kola, I., & Landis, J. (2004). Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug Discovery, 3, 711–715.CrossRefPubMedGoogle Scholar
  2. 2.
    Lee, W. M. (2003). Acute liver failure in the United States. Seminars in Liver Disease, 23, 217–226.CrossRefPubMedGoogle Scholar
  3. 3.
    Hewitt, N. J., Gomez-Lechon, M. J., Houston, J. B., et al. (2007). Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metabolism Reviews, 39, 159–234.CrossRefPubMedGoogle Scholar
  4. 4.
    Gomez-Lechon, M. J., Donato, M. T., Castell, J. V., et al. (2004). Human hepatocytes in primary culture, the choice to investigate drug metabolism in man. Current Drug Metabolism, 5, 443–462.CrossRefPubMedGoogle Scholar
  5. 5.
    Li, A. P., Lu, C., Brent, J. A., et al. (1999). Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. Chemico-Biological Interactions, 121, 17–35.CrossRefPubMedGoogle Scholar
  6. 6.
    Richert, L., Liguori, M. J., Abadie, C., et al. (2006). Gene expression in human hepatocytes in suspension after isolation is similar to the liver of origin, is not affected by hepatocyte cold storage and cryopreservation, but is strongly changed after hepatocyte plating. Drug Metabolism and Disposition, 34, 870–879.CrossRefPubMedGoogle Scholar
  7. 7.
    Rodriguez-Antona, C., Donato, M. T., Boobis, A., et al. (2002). Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells. Xenobiotica, 32, 505–520.CrossRefPubMedGoogle Scholar
  8. 8.
    Gerets, H. H. J., Tilmant, K., Gerin, B., et al. (2012). Characterization of primary human hepatocytes, HepG2 cells and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biology and Toxicology, 28, 69–87.PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., et al. (1998). Embryonic stem cell lines derived from human blastocysts. Science, 282, 1145–1147.CrossRefPubMedGoogle Scholar
  10. 10.
    Takahashi, K., Tanabe, K., Ohnuki, M., et al. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131, 861–872.CrossRefPubMedGoogle Scholar
  11. 11.
    Baxter, M. A., Rowe, C., Alder, J., et al. (2010). Generating hepatic cell lineages from pluripotent stem cells for drug toxicity screening. Stem Cell Research, 5, 4–22.PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Sartipy, P., & Björquist, P. (2011). Concise review: human pluripotent stem cell-based models for cardiac and hepatic toxicity assessment. Stem Cells, 29, 744–748.CrossRefPubMedGoogle Scholar
  13. 13.
    Li, A. P. (2008). Human hepatocytes as an effective alternative experimental system for the evaluation of human drug properties: general concepts and assay procedures. ALTEX, 25, 33–42.PubMedGoogle Scholar
  14. 14.
    Ek, M., Söderdahl, T., Küppers-Munther, B., et al. (2007). Expression of drug metabolizing enzymes in hepatocyte-like cells derived from human embryonic stem cells. Biochemical Pharmacology, 74, 496–503.CrossRefPubMedGoogle Scholar
  15. 15.
    Söderdahl, T., Küppers-Munther, B., Heins, N., et al. (2007). Glutathione transferases in hepatocyte-like cells derived from human embryonic stem cells. Toxicology In Vitro, 21, 929–937.CrossRefPubMedGoogle Scholar
  16. 16.
    Hay, D. C., Fletcher, J., Payne, C., et al. (2008). Highly efficient differentiation of human embryonic stem cells to functional hepatic endoderm requires Activin A and Wnt3a signaling. Proceedings of the National Academy of Sciences of the United States of America, 105, 2301–2306.CrossRefGoogle Scholar
  17. 17.
    Hay, D. C., Zhao, D., Fletcher, J., et al. (2008). Efficient differentiation of hepatocytes from human embryonic stem cells exhibiting markers recapitulating liver development in vivo. Stem Cells, 26, 894–902.CrossRefPubMedGoogle Scholar
  18. 18.
    Song, Z., Cai, J., Liu, Y., et al. (2009). Efficient generation of hepatocyte-like cells from human induced pluripotent stem cells. Cell Research, 19, 1233–1242.CrossRefPubMedGoogle Scholar
  19. 19.
    Basma, H., Soto-Gutiérrez, A., Yannam, G. R., et al. (2009). Differentiation and transplantation of human embryonic stem cell-derived hepatocytes. Gastroenterology, 136, 990–999.PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Brolen, G., Sivertsson, L., Björquist, P., et al. (2010). Hepatocyte-like cells derived from human embryonic stem cells specifically via definitive endoderm and a progenitor stage. Journal of Biotechnology, 145, 84–94.CrossRefGoogle Scholar
  21. 21.
    Duan, Y., Ma, X., Zou, W., et al. (2010). Differentiation and characterization of metabolically functioning hepatocytes from human embryonic stem cells. Stem Cells, 28, 674–686.CrossRefPubMedGoogle Scholar
  22. 22.
    Si-Tayeb, K., Noto, F. K., Nagaoka, M., et al. (2010). Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells. Hepatology, 51, 297–305.PubMedCentralCrossRefPubMedGoogle Scholar
  23. 23.
    Sullivan, G. J., Hay, D. C., Park, I. H., et al. (2010). Generation of functional human hepatic endoderm from human induced pluripotent stem cells. Hepatology, 51, 329–335.PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    Touboul, T., Hannan, N. R., Corbineau, S., et al. (2010). Generation of functional hepatocytes from human embryonic stem cells under chemically defined conditions that recapitulate liver development. Hepatology, 51, 1754–1765.CrossRefPubMedGoogle Scholar
  25. 25.
    Rashid, S. T., Corbineau, S., Hannan, N., et al. (2010). Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. Journal of Clinical Investigation, 120, 3127–3136.PubMedCentralCrossRefPubMedGoogle Scholar
  26. 26.
    Ghodsizadeh, A., Taei, A., Totonchi, M., et al. (2010). Generation of liver disease-specific induced pluripotent stem cells along with efficient differentiation to functional hepatocyte-like cells. Stem Cell Reviews and Reports, 6, 622–632.CrossRefPubMedGoogle Scholar
  27. 27.
    Yildirimman, R., Brolén, G., Vilardell, M., et al. (2011). Human embryonic stem cell derived hepatocyte-like cells as a tool for in vitro hazard assessment of chemical carcinogenicity. Toxicological Sciences, 124, 278–290.PubMedCentralCrossRefPubMedGoogle Scholar
  28. 28.
    Funakoshi, N., Duret, C., Pascussi, J. M., et al. (2011). Comparison of hepatic-like cell production from human embryonic stem cells and adult liver progenitor cells: CAR transduction activates a battery of detoxification genes. Stem Cell Reviews, 7, 518–531.PubMedCentralCrossRefPubMedGoogle Scholar
  29. 29.
    Ulvestad, M., Nordell, P., Asplund, A., et al. (2013). Drug metabolizing enzyme and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells. Biochemical Pharmacology, 86, 691–702.CrossRefPubMedGoogle Scholar
  30. 30.
    Kajiwara, M., Aoi, T., Okita, K., et al. (2012). Donor-dependent variations in hepatic differentiation from human induced pluripotent stem cells. Proceedings of the National Academy of Sciences of the United States of America, 109, 12538–12543.PubMedCentralCrossRefPubMedGoogle Scholar
  31. 31.
    Hannan, N. R., Segeritz, C. P., Touboul, T., et al. (2013). Production of hepatocyte-like cells from human pluripotent stem cells. Nature Protocols, 8, 430–437.PubMedCentralCrossRefPubMedGoogle Scholar
  32. 32.
    Hannan, N. R., Fordham, R. P., Syed, Y. A., et al. (2013). Generation of multipotent foregut stem cells from human pluripotent stem cells. Stem Cell Reports, 1, 293–306.PubMedCentralCrossRefPubMedGoogle Scholar
  33. 33.
    Mikkola, M., Olsson, C., Palgi, J., et al. (2006). Distinct differentiation characteristics of individual human embryonic stem cell lines. BMC Developmental Biology, 6, 40.PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    Osafune, K., Caron, L., Borowiak, M., et al. (2008). Marked differences in differentiation propensity among human embryonic stem cell lines. Nature Biotechnology, 3, 313–315.CrossRefGoogle Scholar
  35. 35.
    Itaba, N., Wairagu, P. M., Aramaki, N., et al. (2014). Nuclear receptor gene alteration in human induced pluripotent stem cells with hepatic differentiation propensity. Hepatology Research, 44(14), 408–439.CrossRefGoogle Scholar
  36. 36.
    Bock, C., Kiskinis, E., Verstappen, G., et al. (2011). Reference maps of human embryonic and induced pluripotent stem cell variation enable high-throughput characterization of pluripotent cell lines. Cell, 144, 439–452.PubMedCentralCrossRefPubMedGoogle Scholar
  37. 37.
    Heins, N., Englund, M. C., Sjöblom, C., et al. (2004). Derivation, characterization, and differentiation of human embryonic stem cells. Stem Cells, 22, 367–370.CrossRefPubMedGoogle Scholar
  38. 38.
    Sjögren-Jansson, E., Zetterström, M., Moya, K., et al. (2005). Large-scale propagation of four undifferentiated human embryonic stem cell lines in a feeder-free culture system. Developmental Dynamics, 233, 1304–1314.CrossRefPubMedGoogle Scholar
  39. 39.
    Caisander, G., Park, H., Frej, K., et al. (2006). Chromosomal integrity maintained in five human embryonic stem cell lines after prolonged in vitro culture. Chromosome Research, 14, 131–137.CrossRefPubMedGoogle Scholar
  40. 40.
    Aguilar-Gallardo, C., Poo, M., Gomez, E., et al. (2010). Derivation, characterization, differentiation, and registration of seven human embryonic stem cell lines (VAL-3, -4, -5, -6M, -7, -8, and -9) on human feeder. In Vitro Cellular and Developmental Biology - Animal, 46, 317–326.CrossRefPubMedGoogle Scholar
  41. 41.
    Funa, N. S., Schachter, K. A., Lerdrup, M., et al. (2015). Beta-Catenin regulates primitive streak induction through collaborative interactions with SMAD2/SMAD3 and OCT4. Cell Stem Cell, 16(6), 639–652.CrossRefPubMedGoogle Scholar
  42. 42.
    Holmgren, G., Sjögren, A. K., Barragan, I., et al. (2014). Long-term chronic toxicity testing using human induced pluripotent stem cell-derived hepatocytes. Drug Metabolism and Disposition, 42, 1401–1406.CrossRefPubMedGoogle Scholar
  43. 43.
    Sartipy, P. (2013). Advancing pluripotent stem cell culture: it is a matter of setting the standard. Stem Cells and Development, 22, 1159–1161.PubMedCentralCrossRefPubMedGoogle Scholar
  44. 44.
    Kim, K., Doi, A., Wen, B., et al. (2010). Epigenetic memory in induced pluripotent stem cells. Nature, 467, 285–290.PubMedCentralCrossRefPubMedGoogle Scholar
  45. 45.
    Ohi, Y., Qin, H., Hong, C., et al. (2011). Incomplete DNA methylation underlies a transcriptional memory of somatic cells in human induced pluripotent stem cells. Nature Cell Biology, 13, 541–549.PubMedCentralCrossRefPubMedGoogle Scholar
  46. 46.
    Bar-Nur, O., Russ, H. A., Efrat, S., et al. (2011). Epigenetic memory and preferential lineage-specific differentiation in induced pluripotent stem cell-derived from human beta-cells. Cell Stem Cell, 9, 17–23.CrossRefPubMedGoogle Scholar
  47. 47.
    Lee, S. B., Seo, D., Choi, D., et al. (2012). Contribution of hepatic lineage stage-specific donor memory to the differential potential of induced mouse pluripotent stem cells. Stem Cells, 30, 997–1007.PubMedCentralCrossRefPubMedGoogle Scholar
  48. 48.
    Ponsoda, X., Pareja, E., Gomez-Lechon, M. J., et al. (2001). Drug biotransformation by human hepatocytes. In vitro/in vivo metabolism by cells from the same donor. Journal of Hepatology, 34, 19–25.CrossRefPubMedGoogle Scholar
  49. 49.
    Kuehl, P., Zhang, J., Lin, Y., et al. (2001). Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genetics, 27, 383–391.CrossRefPubMedGoogle Scholar
  50. 50.
    Takayama, K., Morisaki, Y., Kuno, S., et al. (2014). Prediction of interindividual differences in hepatic functions and drug sensitivity by using human induced pluripotent stem cell-derived hepatocytes. Proceedings of the National Academy of Sciences of the United States of America, 111, 16772–16777.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Annika Asplund
    • 1
    • 2
  • Arvind Pradip
    • 1
    • 3
  • Mariska van Giezen
    • 1
  • Anders Aspegren
    • 1
  • Helena Choukair
    • 1
  • Marie Rehnström
    • 1
  • Susanna Jacobsson
    • 1
  • Nidal Ghosheh
    • 2
  • Dorra El Hajjam
    • 1
  • Sandra Holmgren
    • 1
    • 4
  • Susanna Larsson
    • 1
  • Jörg Benecke
    • 1
  • Mariela Butron
    • 1
  • Annelie Wigander
    • 1
  • Karin Noaksson
    • 1
  • Peter Sartipy
    • 2
    • 5
  • Petter Björquist
    • 1
    • 6
  • Josefina Edsbagge
    • 1
  • Barbara Küppers-Munther
    • 1
    • 2
  1. 1.Takara Bio Europe AB (former Cellartis AB)GothenburgSweden
  2. 2.Systems Biology Research Center, School of BioscienceUniversity of SkövdeSkövdeSweden
  3. 3.Novo Nordisk A/SBagsværdDenmark
  4. 4.Institute of Biomedicine, Sahlgrenska AcademyUniversity of GothenburgGothenburgSweden
  5. 5.AstraZeneca R&D, GMD CVMD GMedMölndalSweden
  6. 6.NovaHep ABGothenburgSweden

Personalised recommendations